Boundless Bio, Inc. has taken a significant step towards expanding its market presence by announcing a proposed merger with Serapha Bio, Inc. This strategic move is designed to enhance Boundless Bio's capabilities and offerings in the pharmaceutical preparations sector. The merger is set to be voted on by shareholders at a special meeting scheduled for December 3, 2026.

The merger agreement, initially signed on June 22, 2026, and amended on August 28, 2026, outlines that Boulder Merger Sub Corp., a wholly owned subsidiary of Boundless Bio, will merge with Serapha, with Serapha surviving as a wholly owned subsidiary of Boundless Bio. This merger is expected to create a combined entity that can leverage the strengths of both companies to drive growth and innovation.

Background

Boundless Bio, Inc. is a publicly traded company on the Nasdaq under the ticker symbol BOLD. It operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company. Its headquarters are located in La Jolla, California.

What the Filing Says

The recent SEC filing states, "Boundless Bio and Serapha Bio entered into an Agreement and Plan of Merger and Reorganization... pursuant to which, among other matters, Boulder Merger Sub Corp. will merge with and into Serapha, with Serapha surviving as a wholly owned subsidiary of Boundless Bio." The filing also details the expected exchange ratio for shares and the implications for stockholders of both companies.

Impact

The merger is expected to significantly impact shareholders of both Boundless Bio and Serapha. Following the merger, Boundless Bio securityholders are projected to own approximately 3.8% of the outstanding shares of the combined company on a fully diluted basis, while former Serapha securityholders are expected to own about 29.3%. Additionally, shares issued in the pre-closing financing are anticipated to represent approximately 66.9% of the combined entity's capital stock.

What's Next

The special meeting of Boundless Bio stockholders is scheduled for December 3, 2026, where they will vote on several proposals related to the merger, including the issuance of shares to Serapha stockholders and a proposed reverse stock split. The filing indicates that the merger cannot be completed without the approval of these proposals.